Cholecystokinin Receptor Antagonist

Cholecystokinin Receptor Antagonists (46):

Cat. No.	Product Name	Effect	Purity

HY-106301

Devazepide	Antagonist	99.58%
Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC₅₀s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders.

HY-118194

A-65186	Antagonist	99.94%
A-65186 is a CCK-A receptor antagonist with the activity of inhibiting CCK8-induced amylase secretion. A-65186 has high binding affinity for pancreatic CCK-A receptors, is more than 500 times more selective for CCK-A receptors than for CCK-B receptors, and can inhibit CCK8-induced amylase secretion.

HY-103354

Proglumide sodium	Antagonist	99.85%
Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities.

HY-B1330

Proglumide	Antagonist	99.84%
Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities.

HY-B1439B

Lorglumide sodium salt	Antagonist	99.19%
Lorglumide sodium salt (CR-1409 sodium salt) is a potent cholecystokinin (CCK) receptor antagonist.

HY-128878

Dexloxiglumide	Antagonist	98.25%
Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide, the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8).

HY-106840A

L-365260 hemihydrate	Antagonist	99.75%
L-365260 hemihydrate is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 hemihydrate interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors.

HY-148656

PNB-001	Antagonist	99.65%
PNB-001 is an orally active CCK2 selective ligand and antagonist. PNB-001 has anti-inflammatory and analgesic activities.

HY-U00360

(Rac)-Sograzepide	Antagonist	98.98%
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.

HY-105226B

CI-988 hemihydrate	Antagonist
CI-988 hemihydrate (PD134308) is a potent, selective and orally active CCK2R (cholecystokinin 2 receptor) antagonist with an IC₅₀ of 1.7 nM for mouse cortex CCK2. CI-988 hemihydrate shows >1600-fold selectivity for CCK2 over CCK1 receptor. CI-988 hemihydrate has anxiolytic and anti-tumor effects.

HY-105257

Pranazepide	Antagonist	99.81%
Pranazepide (FR120480) is a cholecystokinin-A receptor antagonist.

HY-U00062

Tarazepide	Antagonist
Tarazepide is a potent and specific CCK-A receptor antagonist.

HY-101352

LY 225910	Antagonist	98.92%
LY 225910 is a selective antagonist for cholecystokinin receptor (CCK2 receptor), which affects the excitatory response to morphine, and leads to morphine sensitization.

HY-100481

RP 72540	Antagonist
RP 72540 is a selective CCK-B receptor antagonist, with IC₅₀ values of 2.4, 1.2, and 3.8 nM for CCK-B receptors in the guinea pig cerebral cortex, rat cerebral cortex, and mouse brain, respectively. RP 72540 effectively inhibits CCK-8-induced neuronal firing and dose-dependently inhibits gastric acid secretion, making it potentially valuable in studies of acid secretion. RP 72540 is an important tool for investigating the physiological functions of CCK B receptors.

HY-150036

Anthramycin	Antagonist
Anthramycin, a member of the pyrolobenzodiazepine (PBD) family, is a potent antibiotic. Anthramycin has potent antitumor activity. Anthramycin can act as an potent antagonist of cholecystokinin in the central nervous system in mice.

HY-114966

RP73870	Antagonist
RP73870 is an orally active gastrin/cholecystokinin-B receptor antagonist. RP73870 inhibits basal gastric acid secretion in the rat. RP73870 has potent anti-ulcer activity.

HY-120381

PD 136450	Antagonist
PD 136450 (CAM 1189) is an antagonist for cholecystokinin 2 (CCK2). PD 136450 exhibits anti-secretory, anxiolytic and anti-ulcer activities, inhibits gastric acid secretion (IC₅₀=1 mg/kg), and ameliorates the haemorrhagic lesions (IC₅₀=4.7 mg/kg) in rats.

HY-103354A

Proglumide hemicalcium	Antagonist
Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities.

HY-118546

JNJ-17156516	Antagonist
JNJ-17156516 is an orally active, potent, and selective cholecystokinin (CCK)1-receptor antagonist.

HY-169139

Spiroglumide	Antagonist
Spiroglumide (CR-2194) is a selective cholecystokinin B (CCKB) receptor antagonist.

Name
Email *

	Sorry, but the email address you supplied was invalid.